Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTIL and Low-Dose Irradiation in Advanced Solid Tumors
NCT04643574Phase 1Active, not recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Mar 2021
- Primary completion
- Nov 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoTIL in solid tumor, sponsored by Lausanne University Hospital. Primary endpoints: Number of patients who successfully receive NeoTIL-ACT in combination with LDI at Day 0, Toxicity of NeoTIL-ACT in combination with LDI and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
NeoTIL
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04643574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643574.